MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F19%3A00071708" target="_blank" >RIV/00159816:_____/19:00071708 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/19:00111783

Výsledek na webu

<a href="https://link.springer.com/article/10.1007%2Fs10238-019-00574-7" target="_blank" >https://link.springer.com/article/10.1007%2Fs10238-019-00574-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10238-019-00574-7" target="_blank" >10.1007/s10238-019-00574-7</a>

Jazyk výsledku

angličtina

Název v původním jazyce

MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma

Popis výsledku v původním jazyce

None of the currently investigated molecular markers demonstrated sufficient accuracy in prognostication of the renal cell carcinoma (RCC) oncologic outcomes; thus, none of them has been recommended for the application in the routine clinical practice. The role of miR-15a as a potential prognostic marker for RCC is still not unveiled. The aim of our study was to assess the expression of miR-15a in tumor tissues of the patients with RCC and to evaluate the possibility of its usage as a prognostic molecular biomarker of this disease. The retrospective included 64 adult patients with clear cell RCC (ccRCC) in whom radical or partial nephrectomy was conducted. After deparaffinization of formalin-fixed paraffin-embedded (FFPE) ccRCC specimens, the tissue expression of miR-15a was measured using the reverse transcription and quantitative polymerase chain reaction in the real time. For the reference, the expression of miR-15a was estimated in 15 FFPE tissue specimens of the normal renal parenchyma. Survival analysis involved all cases of non-metastatic RCCs (n = 57). Five-year cancer-specific survival (CSS) was estimated by means of the Kaplan-Meier method and was calculated from the date of surgery to the date of death. Patients with the RCC were characterized by significantly upregulated tumor tissue mean levels of miR-15a compared to the healthy controls: 0.10 +/- 2.62 relative units (RU) versus 4.84E - 03 +/- 3.11E - 03 RU (p &lt; 0.001). Overexpression of miR-15a was strongly associated with poor histologic prognostic features of ccRCC. Poorly differentiated tumors tend to have more pronounced upregulation of miR-15a compared to highly differentiated lesions: Mean expression values were 4.57 +/- 3.19 RU for Fuhrman grade 4 versus 0.02 +/- 0.01 RU for Fuhrman grade 1 (p &lt; 0.001). The metastatic involvement of the regional lymphatic nodules (N +) was associated with significantly upregulated miRNA-15a in comparison with N - cases: Mean expression values were 4.92 +/- 2.80 RU versus 1.10 +/- 2.29 RU, respectively (p &lt; 0.001). In patients with miR-15a expression in RCC tissues &lt;= 0.10 RU, mean 5-year CSS was significantly longer compared to patients with expression levels above this threshold: 92.31% (mean duration of survival-59.88 +/- 0.12 months) versus 54.8% (mean duration of survival-49.74 +/- 2.16 months), respectively (p &lt; 0.001). The tissue expression of miR-15a could be used as a potential prognostic molecular biomarker for conventional RCC.

Název v anglickém jazyce

MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma

Popis výsledku anglicky

None of the currently investigated molecular markers demonstrated sufficient accuracy in prognostication of the renal cell carcinoma (RCC) oncologic outcomes; thus, none of them has been recommended for the application in the routine clinical practice. The role of miR-15a as a potential prognostic marker for RCC is still not unveiled. The aim of our study was to assess the expression of miR-15a in tumor tissues of the patients with RCC and to evaluate the possibility of its usage as a prognostic molecular biomarker of this disease. The retrospective included 64 adult patients with clear cell RCC (ccRCC) in whom radical or partial nephrectomy was conducted. After deparaffinization of formalin-fixed paraffin-embedded (FFPE) ccRCC specimens, the tissue expression of miR-15a was measured using the reverse transcription and quantitative polymerase chain reaction in the real time. For the reference, the expression of miR-15a was estimated in 15 FFPE tissue specimens of the normal renal parenchyma. Survival analysis involved all cases of non-metastatic RCCs (n = 57). Five-year cancer-specific survival (CSS) was estimated by means of the Kaplan-Meier method and was calculated from the date of surgery to the date of death. Patients with the RCC were characterized by significantly upregulated tumor tissue mean levels of miR-15a compared to the healthy controls: 0.10 +/- 2.62 relative units (RU) versus 4.84E - 03 +/- 3.11E - 03 RU (p &lt; 0.001). Overexpression of miR-15a was strongly associated with poor histologic prognostic features of ccRCC. Poorly differentiated tumors tend to have more pronounced upregulation of miR-15a compared to highly differentiated lesions: Mean expression values were 4.57 +/- 3.19 RU for Fuhrman grade 4 versus 0.02 +/- 0.01 RU for Fuhrman grade 1 (p &lt; 0.001). The metastatic involvement of the regional lymphatic nodules (N +) was associated with significantly upregulated miRNA-15a in comparison with N - cases: Mean expression values were 4.92 +/- 2.80 RU versus 1.10 +/- 2.29 RU, respectively (p &lt; 0.001). In patients with miR-15a expression in RCC tissues &lt;= 0.10 RU, mean 5-year CSS was significantly longer compared to patients with expression levels above this threshold: 92.31% (mean duration of survival-59.88 +/- 0.12 months) versus 54.8% (mean duration of survival-49.74 +/- 2.16 months), respectively (p &lt; 0.001). The tissue expression of miR-15a could be used as a potential prognostic molecular biomarker for conventional RCC.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30100 - Basic medicine

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical and Experimental Medicine

ISSN

1591-8890

e-ISSN

—

Svazek periodika

19

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

515-524

Kód UT WoS článku

000491035600013

EID výsledku v databázi Scopus

—